Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Hepatocellular Carcinoma | Research

B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma

Authors: Yang Han, Zhe Li, Qi Wu, Hui Liu, Zhiqiang Sun, Yong Wu, Judong Luo

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

B4GALT5 is postulated to be an important protein in sugar metabolism that catalyzes the synthesis of lactosylceramide (LacCer). However, its role in hepatocellular carcinoma (HCC) remains unknown.

Method

We characterized the expression of B4GALT5 in HCC tissue compared to normal tissue, and explored its function of B4GALT5 in HCC by enrichment analysis based on its co-expressed gene set. Next, we checked whether B4GALT5 expression is correlated to immune infiltration level and clinical prognosis in hepatocellular carcinoma. Finally, we verified the expression of B4GALT5 using clinical samples evaluated by RT-PCR, and conducted in vitro experiments with B4GALT5-knockdown HCC cells to investigate the function of B4GALT5 in the HCC cell proliferation, migration and invasion.

Results

We found B4GALT5 mRNA and protein expression levels were significantly high in HCC tissue compared to normal tissue. The enrichment analysis of the gene sets that co-expressed with B4GALT5 showed specificity in HCC-related pathways and functions. Also, the expression pattern of B4GALT5 was significantly related to the immune infiltration level, especially CD4+ T cell and macrophage cells. B4GALT5 higher mRNA expression was associated with poor overall survival (OS) in HCC patients. Furthermore, In vitro experiments showed that depletion of B4GALT5 significantly inhibited HCC cell proliferation, migration and invasion. This study revealed the function and its mediated pathways of B4GALT5 in HCC, indicating that B4GALT5 may serve as a prognostic biomarker of HCC.
Literature
1.
Kucukoglu O, Sowa J-P, Mazzolini GD, Syn W-K, Canbay A. Hepatokines and adipokines in nash-related hepatocellular carcinoma. J Hepatol. 2021; 74(2):442–57.PubMedCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394–424.PubMedCrossRef
3.
Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis b and c virus infection and hepatocellular carcinoma in china: a review of epidemiology and control measures. J Epidemiol. 2011; 21(6):401–16.PubMedPubMedCentralCrossRef
4.
Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of hcc in special populations. J Hepatol. 2021; 74(4):931–43.PubMedCrossRef
5.
Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005; 5(7):526–42.PubMedCrossRef
6.
Yates B, Braschi B, Gray KA, Seal RL, Tweedie S, Bruford EA. Genenames. org: the hgnc and vgnc resources in 2017. Nucleic Acids Res. 2017; 45(D1):D619–25.PubMedCrossRef
7.
De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafè M, Giudetti AM. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Oxidative Med Cell Longev. 2018; 11(4):7512159.
8.
Li S-F, Zhu C-S, Wang Y-M, Xie X-X, Xiao L-L, Zhang Z-C, Tang Q-Q, Li X. Downregulation of β1, 4-galactosyltransferase 5 improves insulin resistance by promoting adipocyte commitment and reducing inflammation. Cell Death Dis. 2018; 9(2):1–14.
9.
Tang W, Li M, Qi X, Li J. β1, 4-galactosyltransferase v modulates breast cancer stem cells through wnt/ β-catenin signaling pathway. Cancer Res Treat: Off J Korean Cancer Assoc. 2020; 52(4):1084.
10.
Rodeheffer C, Shur BD. Targeted mutations in β1, 4-galactosyltransferase i reveal its multiple cellular functions. Biochim Biophys Acta (BBA) - Gen Subj. 2002; 1573(3):258–70.CrossRef
11.
Youakim A, Dubois DH, Shur BD. Localization of the long form of beta-1, 4-galactosyltransferase to the plasma membrane and golgi complex of 3t3 and f9 cells by immunofluorescence confocal microscopy. Proc Natl Acad Sci. 1994; 91(23):10913–17.PubMedPubMedCentralCrossRef
12.
13.
Kang X, Wang N, Pei C, Sun L, Sun R, Chen J, Liu Y. Glycan-related gene expression signatures in human metastatic hepatocellular carcinoma cells. Exp Ther Med. 2012; 3(3):415–22.PubMedCrossRef
14.
Zhou Y, Zhou B, Pache L, Chang M, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523.PubMedPubMedCentralCrossRef
15.
16.
Ruiz E, Rojas TR, Berrospi F, Chávez I, Luque C, Cano L, Doimi F, Pineau P, Deharo E, Bertani S. Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the national cancer institute of peru. Heliyon. 2016; 2(1):00052.CrossRef
17.
De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018; 50(11):1115–23.PubMedCrossRef
18.
Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci. 2019; 14(6):581–94.PubMedPubMedCentralCrossRef
19.
Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015; 21(37):10573.PubMedPubMedCentralCrossRef
20.
Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019; 35(3):347–67.PubMedPubMedCentralCrossRef
21.
Wang Y, Fukuda T, Isaji T, Lu J, Im S, Hang Q, Gu W, Hou S, Ohtsubo K, Gu J. Loss of αl, 6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways. FASEB J. 2015; 29(8):3217–27.PubMedCrossRef
22.
Li S, Liu X-Y, Pan Q, Wu J, Liu Z-H, Wang Y, Liu M, Zhang X-L. Hepatitis c virus-induced fut8 causes 5-fu drug resistance in human hepatoma huh7. 5.1 cells. Viruses. 2019; 11(4):378.PubMedCentralCrossRef
23.
Huang H, Liu Y, Yu P, Qu J, Guo Y, Li W, Wang S, Zhang J. Mir-23a transcriptional activated by runx2 increases metastatic potential of mouse hepatoma cell via directly targeting mgat3. Sci Rep. 2018; 8(1):1–11.
24.
Lu J, Isaji T, Im S, Fukuda T, Kameyama A, Gu J. Expression of n-acetylglucosaminyltransferase iii suppresses α2, 3-sialylation, and its distinctive functions in cell migration are attributed to α2, 6-sialylation levels. J Biol Chem. 2016; 291(11):5708–20.PubMedPubMedCentralCrossRef
25.
Yoshihara T, Satake H, Nishie T, Okino N, Hatta T, Otani H, Naruse C, Suzuki H, Sugihara K, Kamimura E, et al. Lactosylceramide synthases encoded by b4galt5 and 6 genes are pivotal for neuronal generation and myelin formation in mice. PLoS Genet. 2018; 14(8):1007545.CrossRef
26.
Danolic D, Heffer M, Wagner J, Skrlec I, Alvir I, Mamic I, Susnjar L, Banovic M, Danolić D, Puljiz M. Role of ganglioside biosynthesis genetic polymorphism in cervical cancer development. J Obstet Gynaecol. 2020; 40(8):1127–32.PubMedCrossRef
27.
Narayan G, Murty VV. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Futur Oncol. 2010; 6(10):1643–52.CrossRef
28.
Wang D, Zhu Z-Z, Jiang H, Zhu J, Cong W-M, Wen B-J, He S-Q, Liu S-F. Multiple genes identified as targets for 20q13. 12–13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma. Hep Intl. 2015; 9(3):438–46.CrossRef
29.
Parker BL, Thaysen-Andersen M, Fazakerley DJ, Holliday M, Packer NH, James DE. Terminal galactosylation and sialylation switching on membrane glycoproteins upon tnf-alpha-induced insulin resistance in adipocytes. Mol Cell Proteomics. 2016; 15(1):141–53.PubMedCrossRef
30.
Kumagai T, Tanaka M, Yokoyama M, Sato T, Shinkai T, Furukawa K. Early lethality of β-1, 4-galactosyltransferase v-mutant mice by growth retardation. Biochem Biophys Res Commun. 2009; 379(2):456–59.PubMedCrossRef
31.
32.
Nagata M, Izumi Y, Ishikawa E, Kiyotake R, Doi R, Iwai S, Omahdi Z, Yamaji T, Miyamoto T, Bamba T, et al. Intracellular metabolite β-glucosylceramide is an endogenous mincle ligand possessing immunostimulatory activity. Proc Natl Acad Sci. 2017; 114(16):3285–94.CrossRef
33.
34.
Yoshizaki F, Nakayama H, Iwahara C, Takamori K, Ogawa H, Iwabuchi K. Role of glycosphingolipid-enriched microdomains in innate immunity: microdomain-dependent phagocytic cell functions. Biochim Biophys Acta (BBA) - Gen Subj. 2008; 1780(3):383–92.CrossRef
35.
Iwabuchi K. Gangliosides in the immune system: Role of glycosphingolipids and glycosphingolipid-enriched lipid rafts in immunological functions. Gangliosides. 2018; 1804:83–95.CrossRef
36.
Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisäkk P, Kallas K, et al. B4galt6 regulates astrocyte activation during cns inflammation. Nat Med. 2014; 20(10):1147.PubMedPubMedCentralCrossRef
37.
Roessler S, Jia H-L, Budhu A, Forgues M, Ye Q-H, Lee J-S, Thorgeirsson SS, Sun Z, Tang Z-Y, Qin L-X, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010; 70(24):10202–12.PubMedPubMedCentralCrossRef
38.
Ritchie ME, Belinda P, Wu D, Hu Y, Law CW, Wei S, Smyth GK. limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):47.CrossRef
39.
Li P, Xiu WB, Di KL, Xu C, Wang GM, Xia QY, Xiong Q. Large-scale rna-seq transcriptome analysis of 4043 cancers and 548 normal tissue controls across 12 tcga cancer types. Sci Rep. 2015; 5:13413.PubMedPubMedCentralCrossRef
40.
Janet P, Núria Q, àlex B, Jordi DP, Anna BM, Martin B, Ferran S, Furlong LI. Disgenet: a discovery platform for the dynamical exploration of human diseases and their genes. Database. 2015; 4(15):bav028.
41.
Pan JB, Hu SC, Shi D, Cai MC, Li YB, Zou Q, Ji ZL, Arnar P. Pagenbase: A pattern gene database for the global and dynamic understanding of gene function. PLoS ONE. 2013; 8(12):80747.CrossRef
42.
Sturm G, Finotello F, List M. Immunedeconv: An r package for unified access to computational methods for estimating immune cell fractions from bulk rna-sequencing data. 2020.
43.
44.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. Timer: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017; 77(21):108.CrossRef
Metadata
Title
B4GALT5 high expression associated with poor prognosis of hepatocellular carcinoma
Authors
Yang Han
Zhe Li
Qi Wu
Hui Liu
Zhiqiang Sun
Yong Wu
Judong Luo
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09442-2

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue

Research

Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts

Research

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

Research

Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis

Research

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Research

KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer

Research

Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits